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Abstract
Millions of people worldwide currently suffer from serious neurological diseases and injuries
for which there are few, and often no, effective treatments. The paucity of effective interven-
tions is, no doubt, due in large part to the complexity of the disorders, as well as our currently
limited understanding of their pathophysiology. The bleak picture for patients, however, is
also attributable to avoidable impediments stemming from quality concerns in preclinical
research that often escape detection by research regulation efforts. In our essay, we con-
nect the dots between these concerns about the quality of preclinical research and their
potential ethical impact on the patients who volunteer for early trials of interventions
informed by it. We do so in hopes that a greater appreciation among preclinical researchers
of these serious ethical consequences can lead to a greater commitment within the research
community to adopt widely available tools and measures that can help to improve the quality
of research.
For those who have the misfortune of suffering a stroke or being diagnosed with a progressive
neurodegenerative disease, there are few, if any, treatments for them that will either retard or
reverse symptoms, prevent major disability, or extend life. However, some will qualify for early
trials testing novel drugs or biologics, representing what many see as a welcome option.
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Whether they realize it or not, those who enroll in these early trials will be trusting a long line
of research and countless investigators whose preclinical work will have laid the foundation
for the trial.
Unfortunately, the prospects for success for such trials are exceedingly low. For example,
although more than 60 molecules have been investigated in the 22 years since Riluzole received
marketing authorization from the United States Food and Drug Administration (FDA) for
treatment of amyotrophic lateral sclerosis (ALS), there has been only one new FDA-approved
drug, edaravone, as a result of all these trials [1,2]. In the case of Alzheimer disease, although
clinical trials have been conducted for decades, there remains no approved drug that effectively
combats the disease, as the most recent report of a failed phase III trial sadly reminds us [3]. As
for stroke, despite the numerous neuroprotective drugs that ameliorate the consequences of a
stroke in preclinical models, none of these drugs has been effective in patients [4].
This high rate of failure undoubtedly reflects the complexity of neurological diseases and
injuries and the current limits of our understanding of their pathophysiology [5]. Further add-
ing to the scientific challenges is the fact that few animal models mimic complex human brain
phenomena, including human-type cognition, emotion, and behavior [6]. And, given their
high moral status, the nonhuman primates who do share these traits are generally not available
for study, either at all or in sufficient numbers.
Ethical challenges with the design of clinical trials themselves create additional hurdles that
can impede progress. There are often safety concerns associated with novel interventions, such
as the use of genetically modified stem cells, so phase I trials are often initially conducted on
the sickest people with disorders like ALS that cause short life expectancies. This means the
opportunity is lost to look for and learn about delayed safety and efficacy issues that may arise
long after transplantation, information that can prove critical in subsequent initial trials in
other diseases that have longer life expectancies. In addition, since many neurological disor-
ders are disorders of suffering—e.g., severe depression, neuropathic pain—their very nature
creates ethical challenges for both research ethics committees (RECs) and participant recruit-
ment. Other degenerative disorders similarly prove ethically complex to investigate because
they necessitate intervention in prodromal stages that expose “healthy at-risk” individuals to
unproven and possibly unsafe treatments. Further, such studies must be of long duration,
proving costly to industry sponsors.
These challenges notwithstanding, and despite the dedication of researchers, multiple, ubiq-
uitous, and, most importantly, avoidable impediments further hinder the progress sought by
all concerned. (See Fig 1) Impediments stem from a broad range of features of preclinical
research that can cause problems for virtually all early clinical trials. These include, but are not
limited to, matters such as low internal, construct, and external validity; exceedingly low sam-
ple sizes; nonvalidated antibodies and biologicals; and substantial publication bias. Space does
not permit us to review all of these threats to the validity of the results of preclinical transla-
tional research, but meta-research of the last decade has exposed them in great detail [7–17].
To illustrate their magnitude and subsequent potential impact on the patients who enroll in
early clinical trials, we will look first at matters related to publication bias.
If we are going to use data from preclinical studies to inform clinical trials, then the avail-
able data that describe how effective an intervention is for a given disease need to reflect ade-
quately the entirety of data that exist testing such an assertion. This requires the publication of
all experiments and outcomes assessed, irrespective of their findings. Unfortunately, experi-
ments that find a positive effect are substantially more likely to be published than similar
experiments testing the same intervention that find it not to be effective. In addition, studies
that assess multiple outcomes often only report the outcomes that show a positive effect.
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The bias that can result from such selective reporting is apparent in an assessment of animal
studies describing neurological diseases. It observed an excess of significant findings compared
to what was expected, suggesting reporting biases in the literature [18]. In the preclinical stroke
literature, conservative estimates of the magnitude of the impact of publication bias have been
made, and they suggest one in six experiments remain unpublished. This leads to an overesti-
mation of treatment effects of about 30% [19]. Such studies show the extent to which current
overrepresentation of positive studies—as well as the low statistical power, or “winner’s curse,”
of neuroscience studies that reduces the chance that a statistically significant result is indicative
of a true effect [20]—can erroneously lead us to deem an intervention to be substantially more
effective than it is.
Such publication bias and the problems it poses for patients in early trials would be less
prevalent if more preclinical researchers would follow the many recommendations that are
available to improve the design and conduct of in vivo animal experiments [21]. Evidence
from just one example of thoughtful recommendations, the Animal Research: Reporting of In
Vivo Experiments (ARRIVE) guidelines, is illustrative. Developed in 2010 to improve report-
ing about animal research, they are now endorsed by more than 1,000 journals. The most cur-
rent reports about their use show that the preclinical research community remains both largely
unaware of them and recalcitrant in its uptake of them [22].
Fig 1. Avoidable deficiencies in preclinical research cause detrimental ripple effects all along the translation pathway that erode both the safety
and ethics of early clinical trials.
https://doi.org/10.1371/journal.pbio.2006343.g001
PLOS Biology | https://doi.org/10.1371/journal.pbio.2006343 June 6, 2018 3 / 9
Experience with expert guidance from the Stroke Treatment Academic Industry Roundta-
ble (STAIR) is equally troubling because it shows that it is not just individual research teams
that are ignoring useful recommendations that could strengthen early trials. Federal drug
approval agencies do as well. Among other things, STAIR publishes and updates recommenda-
tions for preclinical standards in the development of drugs for acute ischemic stroke [23,24].
These include expert guidance for clinical trialists on preclinical evidence requirements for
launching trials. However, the corresponding European Medicines Agency (EMA) guideline
for planning stroke trials does not refer to any STAIR preclinical recommendations [25], and
the FDA does not provide a stroke-specific guideline.
The cumulative weight of the foregoing considerations shows that patients can enter
early trials based on preclinical studies that may not have been sufficiently powered, whose
investigators may not have been blinded, and the results of which may never have been
replicated. One might hope that regulatory review processes would winnow out such prob-
lematic research, but the evidence on this front as well is far from encouraging. To begin
with, in the US, applications to the FDA to launch initial human studies can be approved
exclusively on the basis of preclinical safety data, not evidence of efficacy, revealing a narrow
focus [26,27].
RECs have a broader focus, since they must make a positive determination that the poten-
tial benefits of a study outweigh its risks. They rely heavily on investigator brochures (IBs) to
help them weigh risks against benefits. A recently completed study about the information
from preclinical efficacy studies (PCESs) produced discouraging results [28]. It reviewed the
nonclinical sections of 109 IBs for phase I/II trials submitted to German RECs over a period of
six years (2010–2015). It found that reporting on PCESs infrequently describes study elements
essential for evaluating those studies, including sample size (26%), baseline characterization of
animals (18%), randomization (4%), sample size calculation (0%), and blinded outcome assess-
ment (0%). For 81% of all IBs, no included PCESs had a reference to published reports. In 82%
of all IBs, preclinical efficacy studies were exclusively positive. The study authors concluded
that most IBs for phase I/II studies do not allow RECs—nor others such as federal regulators,
investigators, or data and safety monitoring boards, for that matter—to systematically appraise
the strength of the supporting preclinical findings.
Collectively, the foregoing considerations about preclinical research raise substantive con-
cerns about whether early trials actually meet the ethical threshold found in all international
codes of research ethics. Those codes stipulate that risks must be minimized and that risks
must be outweighed by anticipated benefits. Equally critical is a minimum threshold for antici-
pated social value of a given trial [29,30]. RECs by necessity must draw upon preclinical safety
and efficacy evidence in their assessment of the risks, benefits, and anticipated social value of
early trials. Given the embedded problems in preclinical evidence of the sorts we have
highlighted, two conclusions are unavoidable. First, the reliability of RECs’ assessments is
questionable, given the documented weaknesses of the evidence they draw upon. Second, it is
clear that trial participants are exposed to much more uncertainty about risks, benefits, and
social value than they should be.
There is, of course, one other important ethics safeguard besides REC review that we can
look to that is meant to stand as a buffer between early studies that receive REC approval and
the people with serious neurological diseases and injuries who are candidates for those studies,
and that is the informed consent process. But available evidence about informed consent also
raises major questions. (See Fig 2) While consent documents are required to quantify risks,
information about benefits is typically tied to the portion of informed consent forms explain-
ing the purpose(s) of the study. Consequently, while forms state study objectives—i.e., what
investigators hope to learn during the course of the trial—and disclose the fact that these
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objectives may not occur, there is no mention of how much uncertainty there is regarding
whether a trial might result in the expected benefits and risks. For example, it is almost a cer-
tainty that no information is ever disclosed to potential volunteers about whether the strength
of the scientific evidence relied upon to launch a trial meets basic standards of reliability, such
as whether critical studies were adequately powered, whether investigators were blinded in
preclinical studies, or whether regulatory approval agencies examined any efficacy data.
Thus, the informed consent process will do little, if anything, to counter patient expecta-
tions that a trial is built on solid science. Nor will it offset the well-documented tendency of
research participants to misunderstand critical aspects of what it means to be in a clinical trial.
Research shows that participants are likely both to misunderstand how the clinical trial will
differ from their regular clinical care, what is known as therapeutic misconception (TM), and
to overestimate the potential benefits of participating in the trial, what is known as therapeutic
misestimation (TME). Both undermine the effectiveness of informed consent for clinical trials
in general and early trials of novel modalities in particular [31–33].
Informed consent processes are further weakened by well-documented problems with exag-
gerated portrayals of, or hype regarding, biomedical research [34,35]. This hype not only
reaches participants through popular media discourse around innovative research; it also
influences the discourse about research within the scientific community itself [36,37]. Hype
can positively dispose clinical investigators toward trial launch and can cause trial participants
Fig 2. Ethically sound informed consent requires disclosure of complete and accurate information about the potential risks and benefits of early
trials. Methodologically deficient preclinical studies preclude such adequate disclosures. This only compounds other well-documented problems in the
informed consent process, resulting in potentially misinformed research participants.
https://doi.org/10.1371/journal.pbio.2006343.g002
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to have unrealistic expectations about their trial as well, as the evidence about both TM and
TME attests. Thus, it is quite likely that most volunteers enter early trials without appreciating
the extent to which they are running the risk that they might make themselves even worse off
than they already are.
The landscape of preclinical research and the clinical trials it supports that we have just
described is the reality faced by those with serious neurological diseases and injuries who
may wish to enter early trials. Their suffering is compounded by the bleak prospects that
we described for breakthrough treatments that might lessen their burdens. We know that
many features of their reality will not be changing anytime soon. First, there is little that can
be done about the ethical complexities intrinsic to the design and conduct of early trials
involving people from the affected populations. Second, regulatory bodies will be slow to
change, as current efforts that began in 2011 to make changes to federal regulations
governing human subject research in the US attest. This means that RECs will continue
to exercise broad and, at times, flawed discretion over the trials they review [38]. And it fur-
ther means that the informed consent process will continue to mask the uncertainty pertain-
ing to the potential for both risks and benefits in early trials, since what information gets
disclosed during the process is largely determined by the requirements set forth by research
regulations.
Some features of the landscape of translational neurosciences that we have described are
subject to change, but only if the research community musters the requisite willingness [39].
Multiple groups have long focused on matters that erode the quality and reliability of research,
and they have promulgated several remedies to help address them [13,40,41]. These include
measures to reduce bias and increase statistical conclusion validity [40,42–46], enforcing
adherence to guidelines and recommendations [21], transparent reporting [47], and discrimi-
nating between exploratory and confirmatory research [48], among others. Adopting these
kinds of reforms can have a positive impact. For example, some recent studies [49,50] have
indicated that reporting of preclinical studies can be improved when journals adapt their
instructions to authors.
How much of a difference widespread uptake of them would make remains unclear.
Definitive evidence is lacking that robust, reliable, and reproducible in vivo modeling can, in
fact, improve the prediction of success in subsequent clinical trials and the protection of
patients against harm. It has to be noted, however, that the current model of drug develop-
ment, as well as its regulatory framework, is based on the assumption that preclinical
research regularly meets critical quality thresholds. Conversely, regardless of the model,
research lacking rigor and reporting results selectively is not fit to either efficiently develop
novel therapeutic strategies or assist RECs to weigh harms and benefits for patients in a
meaningful way.
That is why the limited uptake of proposed remedies to improve the robustness of preclini-
cal research is so troubling. It perpetuates many of the real-life consequences described above
for the patients who volunteer for early trials. If, on the other hand, there were more uptake of
them, the picture presented in Fig 1 could be significantly altered because most of the vulnera-
bilities of the translational process it identifies could at least be mitigated, if not eliminated.
That would mean that patients could have greater trust that regulatory approval authorities
and RECs could consistently draw upon strong evidence when they review and approve trials
investigating new drugs and devices. As a result, the negative downstream consequences that
problematic preclinical research presently bestows on patients could be lessened. That would
mean that the current landscape we have described throughout this essay could be a bit
brighter and the path forward in it a bit clearer.
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